Title Post: No surprise: YouTube, Angry Birds, Instagram and Facebook among 2012′s top apps
Rating:
100%
based on 99998 ratings.
5 user reviews.
Author:
Thanks for visiting the blog, If any criticism and suggestions please leave a comment
By Maggie Coughlan
01/01/2013 at 01:20 PM EST
Jennifer Hudson and Jessica Simpson
Courtesy of Weight Watchers
Now Simpson, 32, and Hudson, 31, have one more similarity to add to the list – they've both shed serious pounds thanks to Weight Watchers.
The spokeswomen for the weight loss company met when they shot their first joint advertisement – which will be available on PEOPLE.com on Wednesday – and discussed their lifelong struggles with their weight and body image.
Hudson says she figured she was "just born that way," while Simpson added that she was "always on some new life-stopping diet."
Simpson – who lost over 50 lbs. on the program – recently announced her pregnancy on Twitter.
But the mother to 7-month-old Maxwell Drew, "will not be following the [weight loss] program during the pregnancy while her weight and well-being are monitored by her obstetrician," Weight Watchers said in a statement.
WASHINGTON (AP) — Secretary of State Hillary Rodham Clinton continues to recover in a New York hospital where she's being treated for a blood clot in her head.
Her doctors say blood thinners are being used to dissolve the clot and they are confident she will make a full recovery. Clinton didn't suffer a stroke or neurological damage from the clot that formed after she suffered a concussion during a fainting spell at her home in early December, doctors said in a statement Monday.
Clinton, 65, was admitted to New York-Presbyterian Hospital on Sunday when the clot turned up on a follow-up exam on the concussion, Clinton spokesman Phillipe Reines said. The clot is located in the vein in the space between the brain and the skull behind the right ear. She will be released once the medication dose for the blood thinners has been established, the doctors said.
In their statement, Dr. Lisa Bardack of the Mount Kisco Medical Group and Dr. Gigi El-Bayoumi of George Washington University said Clinton was making excellent progress and was in good spirits.
Clinton's complication "certainly isn't the most common thing to happen after a concussion" and is one of the few types of blood clots in the skull or head that are treated with blood thinners, said Dr. Larry Goldstein, a neurologist who is director of Duke University's stroke center. He is not involved in Clinton's care.
The area where Clinton's clot developed is "a drainage channel, the equivalent of a big vein inside the skull. It's how the blood gets back to the heart," Goldstein said.
Blood thinners usually are enough to treat the clot and it should have no long-term consequences if her doctors are saying she has suffered no neurological damage from it, Goldstein said.
Clinton returned to the U.S. from a trip to Europe, then fell ill with a stomach virus in early December that left her severely dehydrated and forced her to cancel a trip to North Africa and the Middle East. Until then, she had canceled only two scheduled overseas trips, one to Europe after breaking her elbow in June 2009 and one to Asia after the February 2010 earthquake in Haiti.
Her condition worsened when she fainted, fell and suffered a concussion while at home alone in mid-December as she recovered from the virus.
This isn't the first time Clinton has suffered a blood clot. In 1998, midway through her husband's second term as president, Clinton was in New York fundraising for the midterm elections when a swollen right foot led her doctor to diagnose a clot in her knee requiring immediate treatment.
Clinton had planned to step down as secretary of state at the beginning of President Barack Obama's second term. Whether she will return to work before she resigns remains a question.
Democrats are privately if not publicly speculating: How might her illness affect a decision about running for president in 2016?
After decades in politics, Clinton says she plans to spend the next year resting. She has long insisted she had no intention of mounting a second campaign for the White House four years from now. But the door is not entirely closed, and she would almost certainly emerge as the Democrat to beat if she decided to give in to calls by Democratic fans and run again.
Her age — and thereby health — would probably be a factor under consideration, given that Clinton would be 69 when sworn in, if she were elected in 2016. That might become even more of an issue in the early jockeying for 2016 if what started as a bad stomach bug becomes a prolonged, public bout with more serious infirmity.
Not that Democrats are willing to talk openly about the political implications of a long illness, choosing to keep any discussions about her condition behind closed doors. Publicly, Democrats reject the notion that a blood clot could hinder her political prospects.
"Some of those concerns could be borderline sexist," said Basil Smikle, a Democratic strategist who worked for Clinton when she was a senator. "Dick Cheney had significant heart problems when he was vice president, and people joked about it. He took the time he needed to get better, and it wasn't a problem."
It isn't uncommon for presidential candidates' health — and age — to be an issue. Both in 2000 and 2008, Sen. John McCain, R-Ariz., had to rebut concerns he was too old to be commander in chief or that his skin cancer could resurface.
Beyond talk of future politics, Clinton's three-week absence from the State Department has raised eyebrows among some conservative commentators who questioned the seriousness of her ailment after she canceled planned Dec. 20 testimony before Congress on the deadly attack on the U.S. diplomatic mission in Benghazi, Libya.
Clinton had been due to discuss with lawmakers a scathing report she had commissioned on the attack. It found serious failures of leadership and management in two State Department bureaus were to blame for insufficient security at the facility. Clinton took responsibility for the incident before the report was released, but she was not blamed. Four officials cited in the report have either resigned or been reassigned.
WASHINGTON (Reuters) - Washington's last-minute scramble to step back from a recession-inducing "fiscal cliff" shifted to the Republican-controlled House of Representatives on Tuesday after the Senate approved a bipartisan deal to avoid steep tax hikes and spending cuts.
In a rare late-night show of unity, the Senate voted 89 to 8 to raise some taxes on the wealthy while keeping income taxes low on more moderate income voters.
The bill's prospects were less certain in the House, where a vote had not yet been scheduled. Many conservative Republicans have rejected tax increases on any Americans, no matter how wealthy. Some liberal Democrats were also upset with a complex deal that they thought gave away too much.
Lingering uncertainty over U.S. tax and spending policy has unnerved investors and depressed business activity for months, and lawmakers had hoped to reach a deal before Tuesday, when a broad range of automatic tax increases and spending cuts would begin to punch a $600 billion hole in the economy.
Financial markets have avoided a steep plunge on the assumption that Washington would ultimately avoid pushing the country off the fiscal cliff into a recession.
With financial markets closed for the New Year's Day holiday, lawmakers have one more day to close the deal.
"My district cannot afford to wait a few days and have the stock market go down 300 points tomorrow if we don't get together and do something," Representative Steve Cohen, a Democrat from Tennessee, said on the House floor.
The bill passed by the Senate at around 2 a.m. would raise income taxes on families earning more than $450,000 per year. Low temporary rates that have been in place for less affluent taxpayers for the past decade would be made permanent, along with a range of targeted tax breaks put in place by President Barack Obama in the depths of the 2009 recession.
However, workers would see up to $2,000 more taken out of their paychecks as a temporary payroll tax cut was set to expire.
The bill would also delay an across-the-board 8 percent spending cut to domestic and military programs for two months, and extend jobless benefits for 2 million people who otherwise would see them run out.
Obama in a statement on Monday urged the House to vote. "There's more work to do to reduce our deficits, and I'm willing to do it," he said.
Republicans had hoped to include significant spending cuts in the deal to narrow trillion-dollar budget deficits. Conservatives were already looking forward to the next battle over the debt ceiling, in late February, to extract deficit reduction measures from the Democratic president.
Vice President Joe Biden, who was instrumental in pushing through the Senate measure, was scheduled to address a closed-door meeting of House Democrats. Their support likely will be needed to pass the bill.
Republican members were to meet to discuss "a path forward," a senior aide said.
The meeting could help Republicans leaders decide when to begin consideration of the White House-backed measure. A vote could come later in the day, but was not yet scheduled.
The conservative Club for Growth urged a "no" vote on the Senate measure, saying it would be on its "congressional scorecard" used to challenge members of Congress.
Liberal groups also have urged Democrats to reject the deal.
Richard Trumka, head of the AFL-CIO labor union, wrote on Twitter that the deal does not raise taxes enough on the wealthy and "sets the stage for more hostage taking" by Republicans in future budget confrontations.
Republican Representative Tom Cole said his House colleagues should pass the Senate bill rather than try to change it.
"We ought to take this deal right now, and we'll live to fight another day," Cole said on MSNBC. "Putting to bed this thing before the markets (open on Wednesday) is really a pretty important thing to do."
(Writing by Andy Sullivan; Editing by Fred Barbash and Vicki Allen)
Fabio Campana/European Pressphoto Agency
Dr. Rita Levi-Montalcini, a Nobel Prize-winning neurologist who discovered critical chemical tools that the body uses to direct cell growth and build nerve networks, opening the way for the study of how those processes can go wrong in diseases like dementia and cancer, died on Sunday at her home in Rome. She was 103.
Her death was announced by Mayor Gianni Alemanno of Rome.
“I don’t use these words easily, but her work revolutionized the study of neural development, from how we think about it to how we intervene,” said Dr. Gerald D. Fishbach, a neuroscientist and professor emeritus at Columbia.
Scientists had virtually no idea how embryo cells built a latticework of intricate connections to other cells when Dr. Levi-Montalcini began studying chicken embryos in the bedroom of her house in Turin, Italy, during World War II. After years of obsessive study, much of it at Washington University in St. Louis with Dr. Viktor Hamburger, she found a protein that, when released by cells, attracted nerve growth from nearby developing cells.
In the early 1950s, she and Dr. Stanley Cohen, a biochemist also at Washington University, isolated and described the chemical, known as nerve growth factor — and in the process altered the study of cell growth and development. Scientists soon realized that the protein gave them a new way to study and understand disorders of neural growth, like cancer, or of degeneration, like Alzheimer’s disease, and to potentially develop therapies.
In the years after the discovery, Dr. Levi-Montalcini, Dr. Cohen and others described a large family of such growth-promoting agents, each of which worked to regulate the growth of specific cells. One, called epidermal growth factor and discovered by Dr. Cohen, plays a central role in breast cancer; in part by studying its behavior, scientists developed drugs to combat the abnormal growth.
In 1986, Dr. Levi-Montalcini and Dr. Cohen shared the Nobel Prize in Physiology or Medicine for their work.
Dr. Cohen, now an emeritus professor at Vanderbilt University, said Dr. Levi-Montalcini possessed a rare combination of intuition and passion, as well as biological knowledge. “She had this feeling for what was happening biologically,” he said. “She was an intuitive observer, and she saw that something was making these nerve connections grow and was determined to find out what it was.”
One of four children, Rita Levi-Montalcini was born in Turin on April 22, 1909, to Adamo Levi, an engineer, and Adele Montalcini, a painter, both Italian Jews who traced their roots to the Roman Empire. In keeping with the Victorian customs of the time, Mr. Levi discouraged his three daughters from entering college, fearing that it would interfere with their lives as wives and mothers.
It was not a future that Rita wanted. She had decided to become a doctor and told her father so. “He listened, looking at me with that serious and penetrating gaze of his that caused me such trepidation,” she wrote in her autobiography, “In Praise of Imperfection” (1988). He also agreed to support her.
She graduated summa cum laude from the University of Turin medical school in 1936. Two years later, Mussolini issued a manifesto barring non-Aryan Italians from having professional careers. She began her research anyway, setting up a small laboratory in her home to study chick embryos, inspired by the work of Dr. Hamburger, a prominent researcher in St. Louis who also worked with the embryos.
During World War II, the family fled Turin for the countryside, and in 1943 the invasion by Germany forced them to Florence. The family returned at the close of the war, in 1945, and Dr. Hamburger soon invited Dr. Levi-Montalcini to work for a year in his lab at Washington University.
She stayed on, becoming an associate professor in 1956 and a full professor in 1958. In 1962, she helped establish the Institute of Cell Biology in Rome and became its first director. She retired from Washington University in 1977, becoming a guest professor and splitting her time between Rome and St. Louis.
Italy honored her in 2001 by making her a senator for life.
An elegant presence, confident and passionate, she was a sought-after speaker until late in life. “At 100, I have a mind that is superior — thanks to experience — than when I was 20,” she said in 2009.
She never married and had no children. In addition to her autobiography, she was the author or co-author of dozens of research studies and received numerous professional awards, including the National Medal of Science.
“It is imperfection — not perfection — that is the end result of the program written into that formidably complex engine that is the human brain,” Dr. Levi-Montalcini wrote in her autobiography, “and of the influences exerted upon us by the environment and whoever takes care of us during the long years of our physical, psychological and intellectual development.”
This article has been revised to reflect the following correction:
Correction: December 30, 2012
An earlier version of this obituary misstated the year Mussolini issued a manifesto barring non-Aryan Italians from having professional careers. It was 1938, not 1936.
Follow her odyssey from her messy split with Kris Humphries to her great expectation with Kanye West
Credit: Prahl/Winslow/Splash News Online
Updated: Monday Dec 31, 2012 | 11:45 AM EST
WASHINGTON (AP) — The Food and Drug Administration on Monday approved a Johnson & Johnson tuberculosis drug that is the first new medicine to fight the deadly infection in more than four decades.
The agency approved J&J's pill, Sirturo, for use with older drugs to fight a hard-to-treat strain of tuberculosis that has not responded to other medications. However, the agency cautioned that the drug carries risks of potentially deadly heart problems and should be prescribed carefully by doctors.
Roughly one-third of the world's population is estimated to be infected with the bacteria causing tuberculosis. The disease is rare in the U.S., but kills about 1.4 million people a year worldwide. Of those, about 150,000 succumb to the increasingly common drug-resistant forms of the disease. About 60 percent of all cases are concentrated in China, India, Russia and Eastern Europe.
Sirturo, known chemically as bedaquiline, is the first medicine specifically designed for treating multidrug-resistant tuberculosis. That's a form of the disease that cannot be treated with at least two of the four primary antibiotics used for tuberculosis.
The standard drugs used to fight the disease were developed in the 1950s and 1960s.
"The antibiotics used to treat it have been around for at least 40 years and so the bacterium has become more and more resistant to what we have," said Chrispin Kambili, global medical affairs leader for J&J's Janssen division.
The drug carries a boxed warning indicating that it can interfere with the heart's electrical activity, potentially leading to fatal heart rhythms.
"Sirturo provides much-needed treatment for patients who have don't have other therapeutic options available," said Edward Cox, director of the FDA's antibacterial drugs office. "However, because the drug also carries some significant risks, doctors should make sure they use it appropriately and only in patients who don't have other treatment options."
Nine patients taking Sirturo died in company testing compared with two patients taking a placebo. Five of the deaths in the Sirturo group seemed to be related to tuberculosis, but no explanation was apparent for the remaining four.
Despite the deaths, the FDA approved the drug under its accelerated approval program, which allows the agency to clear innovative drugs based on promising preliminary results.
Last week, the consumer advocacy group Public Citizen criticized that approach, noting the drug's outstanding safety issues.
"The fact that bedaquiline is part of a new class of drug means that an increased level of scrutiny should be required for its approval," the group states. "But the FDA had not yet answered concerns related to unexplained increases in toxicity and death in patients getting the drug."
The FDA said it approved the drug based on two mid-stage studies enrolling 440 patients taking Sirturo. Both studies were designed to measure how long it takes patients to be free of tuberculosis.
Results from the first trial showed most patients taking Sirturo plus older drugs were cured after 83 days, compared with 125 days for those taking a placebo plus older drugs. The second study showed most Sirturo patients were cured after 57 days.
NEW YORK (Reuters) - U.S. stocks jumped on Monday after a deal emerged from negotiations in Washington to avert the "fiscal cliff," sources familiar with the talks said.
Equities surged in a thinly traded session, on track to break a five-day streak of losses, as the sources said a majority of Senate Republicans were expected to support the legislation.
If adopted by Congress and President Barack Obama, the plan would sidestep a combination of tax hikes and spending cuts that many feared could push the economy into recession.
The deal, which would still need to be approved by both the Senate and House of Representatives, would raise tax rates for individuals with annual income over $400,000 a year but permanently extend middle class tax cuts.
"The market just wants this resolved and especially resolved in a way where the impact is pushed as far down the road as possible," said Paul Mendelsohn, chief investment strategist at Windham Financial Services in Charlotte, Vermont. "That is exactly what the market wants and I'm hoping that is what they deliver."
President Barack Obama is scheduled to speak on the fiscal cliff at 1:30 p.m.
"Right now the market is up 70 points, an hour from now we could be down 70 points, it all depends on what these people say," Mendelsohn said.
The Dow Jones industrial average <.dji> was up 50.38 points, or 0.39 percent, at 12,988.49 after trimming some of its gains. The Standard & Poor's 500 Index <.spx> was up 9.73 points, or 0.69 percent, at 1,412.16. The Nasdaq Composite Index <.ixic> was up 31.37 points, or 1.06 percent, at 2,991.68.
The S&P 500 is now up 12.4 percent for the year, compared with a flat performance in 2011. The Dow is about 6.4 percent higher and the Nasdaq is up 15 percent.
Gains in Apple Inc , the most valuable U.S. company, helped lift the Nasdaq. The stock rose 3.2 percent to $525.71, lifting the S&P information technology sector <.gspt> up 1 percent. For the year so far, Apple is up 29.1 percent.
The Dow was lifted by Caterpillar Inc
While a deal on the cliff is not yet official, investors may be ready to take on more risk next year in hopes of a greater reward.
Bank stocks rose after a New York Times report that U.S. regulators are nearing a $10 billion settlement with several banks that would end the government's efforts to hold lenders responsible for faulty foreclosure practices.
Bank of America Corp
Financial stocks were among the strongest of the year, with the S&P financial index surging 24.5 percent for 2012 so far. Bank of America is the top-performing Dow component, with its stock price more than doubling over the past 12 months.
(Editing by Kenneth Barry)
Our most popular Asia posts of 2012, by the number of readers and/or the number of comments:
China Calls for ‘No Delay’ on Gun Controls in U.S. This recent post on China’s reaction to the Newtown shooting tragedy brought nearly 200 comments, some enraged at China’s hypocrisy, some enraged at the American gun lobby and a few saying that China, despite any hypocrisy, wasn’t wrong.
China Demands Apology From U.S. This post, about Chen Guangcheng, the 40-year-old human rights lawyer taken in by the U.S. Embassy in Beijing before leaving for New York, also generated nearly 200 comments.
The Best Countries to Be a Woman — and the Worst. After the recent events in India surrounding the rape and murder of a woman, the debate that ensued in the discussion of this post — whether India really was as bad for women as the poll respondents (experts in gender relations) said; worse than Saudi Arabia and China — takes on a new light.
From Milk to Peas, a Chinese Food-Safety Mess. Many of the 125 comments on this post came from outraged readers in China complaining about their government’s failure to safeguard their lives and their children’s.
Watch Your Language! (In China, They Really Do). Before China shut out most content from The New York Times, the International Herald Tribune and Rendezvous, China was home to the third-largest number of Rendezvous readers, outranked only by the United States and Canada. Ironic.
East Asia’s Sea Disputes: Scar Tissue from War Wounds. This analysis, in August, about Chinese activists being arrested by the Japanese Coast Guard for planting flags on one of the Senkaku/Diaoyu islands, was just one of many seeking to explain a host of Asian territorial disputes, and the rising stakes.
A Telling Language Lesson in Hong Kong. When Leung Chun-ying, the new chief executive of Hong Kong, made his inaugural speech in Mandarin rather than Cantonese, it generated nearly 100 comments that showed the depth of the divide that still separates Hong Kong and the mainland. (As did this post, one of Rendezvous’s first, in January.)
It was not all geopolitics. This post on basketball phenom Jeremy Lin, Did ESPN Cross the Line Into Racism? received more than 100 comments, many touching on the role and view of Asian-Americans in the United States and globally. But our first post on Mr. Lin was back on Feb. 5: Asian-American Christian Basketball Star.
And this story generated nearly 100,000 page views: Finally, Outrage in China Against Bear Farming. Similarly, this story received more than 100 comments: The Slaughter of Elephants in Vietnam Is Nearly Complete.
‘Gangnam Style’ Becomes Most-Watched Video Ever on YouTube — 805 Million Views. Of course, the video by the K-pop star Psy has since surpassed the billion-view mark. But the comments, and those on an earlier post, showed the ambivalence many Asians felt toward the image of Asian men they said Psy was portraying.
12/29/2012 at 12:00 PM ET
Bill Davila/Startraks
It’s been a year of ups and downs for Katie Holmes, but she’s going out on a high note. Her effortlessly chic outfit earned top honors this week, making her the final best dressed star of 2012.
The stellar look consisted of a fuchsia Narciso Rodriguez dress and champagne bow-accented heels, topped off with an unexpected olive-green military-inspired trench worn to The Late Show with David Letterman in N.Y.C. The winning ensemble was a bright departure for the star, who tends to opt for more subdued colors. And the risk paid off because more than 6,000 PEOPLE.com readers gave it their style seal of approval.
PHOTOS: SEE THE TOP 10 BEST DRESSED STARS ON PEOPLE.COM THIS WEEK!
In a close second is Jessica Chastain (who had the number-one spot last week) in a leopard-print mini and a black coat, plus tights and lace-up boots, which she slipped into after her Broadway show in N.Y.C.
Click here to check out who else ranked in the top 10 and vote for your favorite looks of the week. Tell us: Does Holmes deserve the top spot? If not, who does?
–Jennifer Cress
Copyright © News tetchily. All rights reserved.
Design And Business Directories